Eli Lilly’s experimental weight loss pill, orforglipron phase 3 clinical trial result update
Eli Lilly’s experimental once-daily pill, orforglipron, has shown promising Phase 3 trial results, helping over 3,000 adults lose an average…
What’s Your Real Age? Meet the Metabolic Age Calculator!
We all know our birthday, the day that marks our chronological age. But what if your body is aging at…
The Evolution of Obesity: Origins and Prevention
Early History and Evolution of Obesity Ancient Existence: Evidence of obesity dates back over 25,000 years, as depicted in Stone…
The Risky Rise of DIY Weight-Loss Drugs: Americans Turning to Unregulated Imports
As demand for weight-loss medications like Wegovy (semaglutide) and Zepbound (tirzepatide) skyrockets, a growing number of Americans are bypassing traditional healthcare systems and turning…
10 quick-tips to help tackle obesity in the USA
More than 70 million American adults—equally split between 35 million men and 35 million women—are classified as obese. Additionally, 99…
Diabesity: The Rising Challenge of Diabetes and Obesity and How Biocon is Taking the Lead
In the world of modern healthcare, there’s a new term that’s creating waves: Diabesity. Coined to capture the dual epidemic…
Retatrutide: The Next-Gen ‘Triple G’ Weight Loss Drug Shows Promising Results
Retatrutide is a promising experimental weight loss drug under development by Eli Lilly. Known as the “Triple G” drug, it…